By leveraging lncRNA inhibition (IGFL2-AS1 ASOs) and siRNA-mediated VEGFR-2 suppression through nanoparticle-mediated delivery systems, researchers are developing novel approaches to enhance drug efficacy and tumor selectivity in RCC treatment. This evidence concerns the gene KDR and renal cell adenocarcinoma.